MOUD 2.0: a clinical algorithm and implementation evaluation protocol for sublingual and injectable buprenorphine treatment of opioid use disorder
BackgroundPrimary care is the initial contact point for most patients with opioid use disorder (OUD) but lacks tools for guiding treatment. Only a small fraction of patients access evidence-based care. Long-acting injectable buprenorphine has potential to improve medication adherence and program ret...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1383695/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592290674114560 |
|---|---|
| author | Brandon L. Joa Eric N. Fung Michael S. Weinstein Lara C. Weinstein Lara C. Weinstein |
| author_facet | Brandon L. Joa Eric N. Fung Michael S. Weinstein Lara C. Weinstein Lara C. Weinstein |
| author_sort | Brandon L. Joa |
| collection | DOAJ |
| description | BackgroundPrimary care is the initial contact point for most patients with opioid use disorder (OUD) but lacks tools for guiding treatment. Only a small fraction of patients access evidence-based care. Long-acting injectable buprenorphine has potential to improve medication adherence and program retention in low-barrier primary care treatment settings. We present the first clinical decision support algorithm incorporating long-acting buprenorphine (LAIB) in primary care. We include a protocol for a future evaluation of the algorithm’s implementation process, “Medication for Opioid Use Disorder (MOUD) 2.0,” at a housing and integrated care clinic at a Federally Qualified Health Center.MethodsLiterature review and expert consensus informed creation of the algorithm, which underwent iterative development with feedback from clinicians, staff, and patients. Patients are categorized by adherence to therapy and retention in the program, with recommendations for each category. Adherence is determined by urine screen supplemented by self-report. To ensure all patients in this high morbidity and mortality risk population are treated, we will treat patients as their own controls in the evaluation, with potential for multisite comparisons. We will present descriptive statistics for adherence proportion before and after MOUD 2.0 implementation, testing for differences using McNemar’s test. We will then present pre- and post-implementation unadjusted six-month survival curves for retention.DiscussionLAIB is incorporated as an alternative or adjunctive treatment for patients refractory to sublingual buprenorphine and as an initial treatment for selected patients. We developed an algorithm with 4-, 8-, and 12-week decision points to guide treatment for patients with varying levels of response to sublingual buprenorphine and LAIB. This clinical decision tool incorporates LAIB among treatment options for OUD in primary care settings. The protocol will evaluate the algorithm’s implementation, presenting a replicable method for assessing adherence and retention among high-risk patients in similar settings. |
| format | Article |
| id | doaj-art-70e5a452201142b280d7485b367ea0ad |
| institution | Kabale University |
| issn | 1664-0640 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj-art-70e5a452201142b280d7485b367ea0ad2025-01-21T10:52:08ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402025-01-011510.3389/fpsyt.2024.13836951383695MOUD 2.0: a clinical algorithm and implementation evaluation protocol for sublingual and injectable buprenorphine treatment of opioid use disorderBrandon L. Joa0Eric N. Fung1Michael S. Weinstein2Lara C. Weinstein3Lara C. Weinstein4Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United StatesDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United StatesIntegrated Care Clinic, Project HOME Healthcare Services, Philadelphia, PA, United StatesSidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United StatesIntegrated Care Clinic, Project HOME Healthcare Services, Philadelphia, PA, United StatesBackgroundPrimary care is the initial contact point for most patients with opioid use disorder (OUD) but lacks tools for guiding treatment. Only a small fraction of patients access evidence-based care. Long-acting injectable buprenorphine has potential to improve medication adherence and program retention in low-barrier primary care treatment settings. We present the first clinical decision support algorithm incorporating long-acting buprenorphine (LAIB) in primary care. We include a protocol for a future evaluation of the algorithm’s implementation process, “Medication for Opioid Use Disorder (MOUD) 2.0,” at a housing and integrated care clinic at a Federally Qualified Health Center.MethodsLiterature review and expert consensus informed creation of the algorithm, which underwent iterative development with feedback from clinicians, staff, and patients. Patients are categorized by adherence to therapy and retention in the program, with recommendations for each category. Adherence is determined by urine screen supplemented by self-report. To ensure all patients in this high morbidity and mortality risk population are treated, we will treat patients as their own controls in the evaluation, with potential for multisite comparisons. We will present descriptive statistics for adherence proportion before and after MOUD 2.0 implementation, testing for differences using McNemar’s test. We will then present pre- and post-implementation unadjusted six-month survival curves for retention.DiscussionLAIB is incorporated as an alternative or adjunctive treatment for patients refractory to sublingual buprenorphine and as an initial treatment for selected patients. We developed an algorithm with 4-, 8-, and 12-week decision points to guide treatment for patients with varying levels of response to sublingual buprenorphine and LAIB. This clinical decision tool incorporates LAIB among treatment options for OUD in primary care settings. The protocol will evaluate the algorithm’s implementation, presenting a replicable method for assessing adherence and retention among high-risk patients in similar settings.https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1383695/fullMOUDlow-barrierunderserved medicineharm reductionsubstance use disorder |
| spellingShingle | Brandon L. Joa Eric N. Fung Michael S. Weinstein Lara C. Weinstein Lara C. Weinstein MOUD 2.0: a clinical algorithm and implementation evaluation protocol for sublingual and injectable buprenorphine treatment of opioid use disorder Frontiers in Psychiatry MOUD low-barrier underserved medicine harm reduction substance use disorder |
| title | MOUD 2.0: a clinical algorithm and implementation evaluation protocol for sublingual and injectable buprenorphine treatment of opioid use disorder |
| title_full | MOUD 2.0: a clinical algorithm and implementation evaluation protocol for sublingual and injectable buprenorphine treatment of opioid use disorder |
| title_fullStr | MOUD 2.0: a clinical algorithm and implementation evaluation protocol for sublingual and injectable buprenorphine treatment of opioid use disorder |
| title_full_unstemmed | MOUD 2.0: a clinical algorithm and implementation evaluation protocol for sublingual and injectable buprenorphine treatment of opioid use disorder |
| title_short | MOUD 2.0: a clinical algorithm and implementation evaluation protocol for sublingual and injectable buprenorphine treatment of opioid use disorder |
| title_sort | moud 2 0 a clinical algorithm and implementation evaluation protocol for sublingual and injectable buprenorphine treatment of opioid use disorder |
| topic | MOUD low-barrier underserved medicine harm reduction substance use disorder |
| url | https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1383695/full |
| work_keys_str_mv | AT brandonljoa moud20aclinicalalgorithmandimplementationevaluationprotocolforsublingualandinjectablebuprenorphinetreatmentofopioidusedisorder AT ericnfung moud20aclinicalalgorithmandimplementationevaluationprotocolforsublingualandinjectablebuprenorphinetreatmentofopioidusedisorder AT michaelsweinstein moud20aclinicalalgorithmandimplementationevaluationprotocolforsublingualandinjectablebuprenorphinetreatmentofopioidusedisorder AT laracweinstein moud20aclinicalalgorithmandimplementationevaluationprotocolforsublingualandinjectablebuprenorphinetreatmentofopioidusedisorder AT laracweinstein moud20aclinicalalgorithmandimplementationevaluationprotocolforsublingualandinjectablebuprenorphinetreatmentofopioidusedisorder |